Welcome to our dedicated page for scPharmaceuticals news (Ticker: SCPH), a resource for investors and traders seeking the latest updates and insights on scPharmaceuticals stock.
scPharmaceuticals Inc. (NASDAQ: SCPH) is a clinical-stage pharmaceutical company dedicated to revolutionizing the administration of infused therapies. Headquartered in Burlington, MA, the company is spearheading advancements in patient care through its proprietary platform that enables subcutaneous administration of treatments traditionally limited to intravenous (IV) delivery. This innovative approach aims not only to improve patient outcomes but also to significantly reduce healthcare costs.
The company’s flagship product, Furoscix, is a patented furosemide formulation designed for subcutaneous use via the wearable, portable sc2Wear Infusor. Furoscix targets the treatment of edema in heart failure patients, offering them a convenient and effective alternative to traditional IV therapies. With a focus on self-administration, scPharmaceuticals is paving the way for outpatient care of acute conditions.
Recent achievements have bolstered scPharmaceuticals’ position in the pharmaceutical landscape. The company generated $6.1 million in product revenue for the first quarter of 2024, a marked increase from $2.1 million in the same period of the previous year. This growth reflects the rising demand for Furoscix and the successful execution of their commercial strategy.
Moreover, scPharmaceuticals is actively pursuing long-term growth initiatives for Furoscix. These include expanding its indication to include NYHA Class IV heart failure patients and chronic kidney disease, both pending FDA review. Another promising development is the initiation of a pharmacokinetic study to support a low-volume auto-injector version of Furoscix, aimed at providing greater flexibility in treatment options.
The company’s financial health remains robust, with strategic investments in research and development, as well as selling, general, and administrative expenses to support its growth trajectory. Despite reporting a net loss of $14.1 million for the first quarter of 2024, compared to $11.2 million for the first quarter of 2023, scPharmaceuticals remains focused on driving forward with its innovative solutions and strategic partnerships.
For more information, please visit www.scPharmaceuticals.com.
scPharmaceuticals Inc. (Nasdaq: SCPH) announced that John Tucker, its President & CEO, will present virtually at the SVB Securities Global Biopharma Conference on February 16, 2023, at 11:20 am ET. During this conference, Tucker will also engage in one-on-one meetings with investors. The company focuses on optimizing infused therapies and reducing healthcare costs, particularly through self-administrable treatments for heart failure and infectious diseases. Headquartered in Burlington, MA, scPharmaceuticals aims to enhance outpatient care while improving health outcomes.
scPharmaceuticals Inc. (Nasdaq: SCPH) plans to commercially launch FUROSCIX (furosemide injection) on February 20, 2023. This product is designed for the outpatient treatment of congestion due to fluid overload in patients with NYHA Class II and III chronic heart failure. The On-Body Infusor will deliver a single dose of 80 mg, and the medication is not for emergency situations. CEO John Tucker notes that Medicare and Medicaid beneficiaries will have access from day one, with discussions ongoing to expand reimbursement coverage. Management will provide detailed updates during the fourth quarter earnings call scheduled for March.
scPharmaceuticals Inc. has appointed Rachael Nokes as its new Chief Financial Officer, bringing over 20 years of leadership experience in life sciences finance.
Previously the Senior Vice President of Finance at the company, Nokes is expected to lead financial strategies as the firm prepares for the commercial launch of FUROSCIX®. This drug is aimed at treating fluid overload in chronic heart failure patients. Nokes's extensive background includes significant roles at BG Medicine Inc. and PriceWaterhouseCoopers, enhancing her capability in managing public-company finance functions.
scPharmaceuticals Inc. (Nasdaq: SCPH) announced that CEO John Tucker will participate in the 12th Annual LifeSci Partners Corporate Access Event on January 9-10, 2023, in San Francisco. The company focuses on developing products to optimize infused therapies, improve patient care, and reduce healthcare costs. Their key initiatives aim to facilitate outpatient treatment for acute conditions, particularly in heart failure and infectious diseases through subcutaneous self-administration of IV-strength therapies. More details regarding the event can be found on their website.
scPharmaceuticals Inc. (Nasdaq: SCPH) announced a public offering of 6,620,000 shares of common stock at $5.25 each, alongside a prefunded warrant for 2,905,000 additional shares at $5.249 each. The total gross proceeds are projected at approximately $50 million, prior to expenses. The offering is set to close on November 25, 2022, pending customary conditions. SVB Securities and Cowen are leading the offering. The securities are registered under a shelf registration statement filed with the SEC.
scPharmaceuticals Inc. (Nasdaq: SCPH) announced FDA marketing approval for FUROSCIX, a self-administered, subcutaneous diuretic for chronic heart failure treatments, marking a potential breakthrough in patient care. The company secured a $100 million debt financing agreement to aid commercialization efforts, with a planned launch in Q1 2023. Financially, third-quarter results showed a net loss of $10.2 million, while cash reserves decreased to $45.4 million. The adjusted net loss guidance for 2022 is now $38 to $41 million, a reduction from prior estimates.
scPharmaceuticals Inc. (Nasdaq: SCPH), a company focused on optimizing infused therapies, will have its President & CEO, John Tucker, present at the Jefferies London Healthcare Conference on November 16 at 5:35 pm GMT (12:35 pm ET). The event will be accessible via a live webcast in the Investor Relations section of their website. The company specializes in developing products to reduce healthcare costs and improve patient outcomes, particularly in heart failure and infectious diseases.
scPharmaceuticals Inc. (Nasdaq: SCPH) announced a conference call on November 9, 2022, at 4:30 p.m. ET to discuss third-quarter financial results and provide a business update. The call will be accessible via phone or through an audio webcast. The company focuses on optimizing infused therapies to enhance patient care and reduce healthcare costs, with key programs on subcutaneous, self-administered treatments for heart failure and infectious diseases.
scPharmaceuticals Inc. announced FDA approval for FUROSCIX (furosemide injection), designed for treating congestion in adults with Class II/III chronic heart failure. The unique formulation allows for subcutaneous administration at home via the On-Body Infusor, ensuring 99.6% bioavailability and comparable diuresis to intravenous treatments. FUROSCIX will be commercially launched in Q1 2023, addressing a significant market potential of $5.9 billion in the U.S. This innovation aims to reduce hospital admissions among heart failure patients, enhancing patient care and healthcare cost efficiency.
scPharmaceuticals Inc. (SCPH) announced a $100 million secured debt facility with Oaktree Capital Management to support the U.S. launch of FUROSCIX, approved by the FDA on October 7, 2022. The financing includes an immediate $50 million upon signing definitive agreements, with another $50 million contingent on meeting specific commercial milestones. The debt facility, with a capped interest rate of 11.75%, will enable the company to repay existing debt and facilitate its commercial launch efforts.
FAQ
What is the current stock price of scPharmaceuticals (SCPH)?
What is the market cap of scPharmaceuticals (SCPH)?
What is scPharmaceuticals Inc.?
What is Furoscix?
Where is scPharmaceuticals headquartered?
How much revenue did scPharmaceuticals generate in Q1 2024?
What are the future plans for Furoscix?
What are the benefits of scPharmaceuticals' platform?
What recent financial results did scPharmaceuticals report?
What is the sc2Wear Infusor?
Who are the key contacts for more information?
What is scPharmaceuticals' approach to outpatient care?
